Novartis’ treatment of multiple myeloma was granted orphan designation by the FDA, according to a post to the agency’s website. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVS:
- Avrobio exploring potential sale after approach, Street Insider says
- Immix Biopharma doses first two patients in Phase 1b/2a combination trial
- Novartis’ Sandoz BLA for proposed biosimilar denosumab accepted by FDA
- Novartis (NYSE:NVS) Down on Sluggish Q4 Sales
- Novartis sees core operating income to grow mid single digit percentage in 2023